Erratum to "Diagnosis and treatment of chronic lymphocytic leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia" [Rev Bras Hematol Hemoter. 2016;38(4):346–357]

Celso Arrais Rodrigues^a,b,*, Matheus Vescovi Gonc¸alves^a,c, Maura Rosane Valério Ikoma^d, Irene Lorand-Metze^e, André Domingues Pereira^b, Danielle Leão Cordeiro de Farias^f, Maria de Lourdes Lopes Ferrari Chauffaille^a,c, Rony Schaffel^g, Eduardo Flávio Oliveira Ribeiro^h, Talita Silveira da Rocha^i,j, Valeria Buccheri^k, Yuri Vasconcelos^l, Vera Lúcia de Piratininga Figueiredo^m, Carlos Sérgio Chiattone^j,n, Mihoko Yamamoto^a, on behalf of the Brazilian Group of Chronic Lymphocytic Leukemia

^a Universidade Federal de São Paulo

^b Hospital Sírio Libanês, São Paulo, SP, Brazil

^c Fleury Medicina e Saúde, São Paulo, SP, Brazil

^d Hospital Amaral Carvalho, Jaú, SP, Brazil

^e Universidade Estadual de Campinas

^f Universidade Federal de Goiás

^g Universidade Federal do Rio de Janeiro

^h Hospital Santa Lúcia, Brasília, DF, Brazil

ⁱ A.C Camargo Cancer Center, São Paulo, SP, Brazil

^j Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil

^k Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil

^l Instituto Goiano de Oncologia e Hematologia (INGOH), Goiânia, GO, Brazil

^m Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, SP, Brazil

ⁿ Hospital Samaritano, São Paulo, SP, Brazil

^*Corresponding author at: Universidade Federal de São Paulo (UNIFESP), Rua Doutor Diogo de Faria, 824, Vila Clementino, 04037-002 São Paulo, SP, Brazil. [e-mail] (C.A. Rodrigues).

In the article "Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia", published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction:

2) Relapsed first-line treatment:

1. Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)

2. Progress within 24 months:

   • - ‘Go-go' patients: ibrutinib

     • Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab

   • - ‘Slow-go' patients: ibrutinib

     • Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite

Publication Dates

• Publication in this collection
  Jan-Mar 2017